Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Decitabine and guadecitabine are hypomethylating agents (HMAs) that exert inhibitory effects against cancer cells. This includes stimulation of anti-tumor immunity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients. Treatment of AML and MDS patients with the HMAs confers up...

Full description

Bibliographic Details
Main Authors: Kah Keng Wong, Rosline Hassan, Nik Soriani Yaacob
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Oncology
Subjects:
acute myeloid leukemia
myelodysplastic syndromes
hypomethylating agents
cancer vaccine
immune checkpoint
chimeric antigen receptor-engineered (CAR)-T cell therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.624742/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.624742/full

Similar Items